Answers are grounded in this paper and cite their sources.
The identification of cell-free fetal DNA (cffDNA) in maternal plasma in 1997 heralded the most significant change in obstetric care for decades, with the advent of safer screening and diagnosis based on analysis of maternal blood. Here, we describe how the technological advances offered by next-generation sequencing have allowed for the development of a highly sensitive screening test for aneuploidies as well as definitive prenatal molecular diagnosis for some monogenic disorders.
No takes yet. Share an insight, caveat, or question.
Chitty et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: